1. APO-Mometasone nasal spray recalled due to contamination

   News item 02 March 2024 Pages: 1 - 1

2. CDER drug safety priorities 2023

   News item 02 March 2024 Pages: 2 - 2

3. DPP-4 inhibitor-related pemphigoid

   News item 02 March 2024 Pages: 3 - 3

4. FDA medication safety tips for older adults

   News item 02 March 2024 Pages: 4 - 4

5. FDA withdraws approval of melphalan flufenamide

   News item 02 March 2024 Pages: 5 - 5

6. Four lots of Audrina 28 birth control pills have misprinted stickers

   News item 02 March 2024 Pages: 6 - 6

7. Neurodevelopment disorders after in utero exposure to topiramate

   News item 02 March 2024 Pages: 7 - 7

8. New measures regarding risk of neurodevelopmental disorders in children after paternal exposure to valproate

   News item 02 March 2024 Pages: 8 - 8

9. Oral dexibuprofen-related DRESS syndrome

   News item 02 March 2024 Pages: 9 - 9

10. Recommendations on strengthening pharmacovigilance in Africa

    News item 02 March 2024 Pages: 10 - 10

11. COVID-19 vaccine-related audiovestibular AEs

    Clinical study 02 March 2024 Pages: 11 - 11

12. Immune checkpoint inhibitor-related risk of pulmonary AEs

    Clinical study 02 March 2024 Pages: 12 - 12

13. Other adverse reaction research

    News item 02 March 2024 Pages: 13 - 13

14. Acarbose/metformin

    Case report 02 March 2024 Pages: 14 - 14

15. Adalimumab/Methotrexate

    Case report 02 March 2024 Pages: 15 - 15

16. Adalimumab/Ustekinumab

    Case report 02 March 2024 Pages: 16 - 16

17. Albumin-human/sodium-chloride

    Case report 02 March 2024 Pages: 17 - 17

18. Alirocumab

    Case report 02 March 2024 Pages: 18 - 18

19. Allopurinol/Carbamazepine

    Case report 02 March 2024 Pages: 19 - 19

20. Amiodarone/bisoprolol

    Case report 02 March 2024 Pages: 20 - 20

21. Amiodarone/Diltiazem

    Case report 02 March 2024 Pages: 21 - 21

22. Amiodarone/Remdesivir

    Case report 02 March 2024 Pages: 22 - 22

23. Amlodipine/cabozantinib

    Case report 02 March 2024 Pages: 23 - 23

24. Antineoplastics

    Case report 02 March 2024 Pages: 24 - 24

25. Antineoplastics

    Case report 02 March 2024 Pages: 25 - 25

26. Antineoplastics

    Case report 02 March 2024 Pages: 26 - 26

27. Antineoplastics

    Case report 02 March 2024 Pages: 27 - 27

28. Apalutamide

    Case report 02 March 2024 Pages: 28 - 28

29. Aripiprazole

    Case report 02 March 2024 Pages: 29 - 29

30. Azathioprine/Ciclosporin/Rituximab

    Case report 02 March 2024 Pages: 30 - 30

31. Azathioprine/Hydroxychloroquine/Steroids

    Case report 02 March 2024 Pages: 31 - 31

32. Azathioprine/Paracetamol/Tofacitinib

    Case report 02 March 2024 Pages: 32 - 32

33. AZD-1222/Elasomeran

    Case report 02 March 2024 Pages: 33 - 33

34. AZD-1222/Methylprednisolone/Prednisolone

    Case report 02 March 2024 Pages: 34 - 34

35. BCG

    Case report 02 March 2024 Pages: 35 - 35

36. Bevacizumab/epirubicin/paclitaxel

    Case report 02 March 2024 Pages: 36 - 36

37. Blinatumomab

    Case report 02 March 2024 Pages: 37 - 37

38. Buprenorphine/naloxone withdrawal

    Case report 02 March 2024 Pages: 38 - 38

39. Camrelizumab

    Case report 02 March 2024 Pages: 39 - 39

40. Ceftazidime/Doxycycline/Vancomycin

    Case report 02 March 2024 Pages: 40 - 40

41. Ceftriaxone

    Case report 02 March 2024 Pages: 41 - 41

42. Celecoxib

    Case report 02 March 2024 Pages: 42 - 42

43. Certolizumab-pegol/methotrexate

    Case report 02 March 2024 Pages: 43 - 43

44. Chlorhexidine

    Case report 02 March 2024 Pages: 44 - 44

45. Chlormethine/mogamulizumab/steroids

    Case report 02 March 2024 Pages: 45 - 45

46. Cisplatin

    Case report 02 March 2024 Pages: 46 - 46

47. Cisplatin

    Case report 02 March 2024 Pages: 47 - 47

48. Cisplatin/etoposide

    Case report 02 March 2024 Pages: 48 - 48

49. Cisplatin/Gemcitabine/Paclitaxel

    Case report 02 March 2024 Pages: 49 - 49

50. Clarithromycin

    Case report 02 March 2024 Pages: 50 - 50